These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37750738)

  • 21. CD244 represents a new therapeutic target in head and neck squamous cell carcinoma.
    Agresta L; Lehn M; Lampe K; Cantrell R; Hennies C; Szabo S; Wise-Draper T; Conforti L; Hoebe K; Janssen EM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type I conventional dendritic cells and CD8
    Kirchner J; Plesca I; Rothe R; Resag A; Löck S; Benešová I; Rupp L; Linge A; Wehner R; Krause M; Schmitz M
    Front Immunol; 2024; 15():1414298. PubMed ID: 38938577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.
    Zhong Z; Hong M; Chen X; Xi Y; Xu Y; Kong D; Deng J; Li Y; Hu R; Sun C; Liang J
    BMC Med Genomics; 2020 Mar; 13(1):57. PubMed ID: 32228580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive review regarding the association of E2Fs with the prognosis and immune infiltrates in human head and neck squamous cell carcinoma.
    Du W; Xia X; Gou Q; Xie Y; Gao L
    Asian J Surg; 2024 May; 47(5):2106-2121. PubMed ID: 38320907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overall assessment of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: time to take notice.
    Almangush A; Leivo I; Mäkitie AA
    Acta Otolaryngol; 2020 Mar; 140(3):246-248. PubMed ID: 32022615
    [No Abstract]   [Full Text] [Related]  

  • 27. Establishment and validation of a tumor-infiltrating γδT cell related prognostic gene signature in head and neck squamous cell carcinoma.
    Lu Y; Xiang Z; Wang W; Yun B; Yi C; Zhang M; Xie N; Wang C; Zhuang Z
    Int Immunopharmacol; 2024 May; 132():112054. PubMed ID: 38608477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Highlighting immune features of the tumor ecosystem and prognostic value of Tfh and Th17 cell infiltration in head and neck squamous cell carcinoma by single-cell RNA-seq.
    Tian Y; Liu C; Yang W; Li X; Zhang M; Xiong Y; Ren X; Ma Z; Jin X; Wu Y; Dong X; Hu N; Xie Z; Qin Y; Wu S
    Cancer Immunol Immunother; 2024 Aug; 73(10):187. PubMed ID: 39093451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Novel Biomarkers for Predicting Prognosis and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma Based on ceRNA Network and Immune Infiltration Analysis.
    Guo Y; Pan WK; Wang ZW; Su WH; Xu K; Jia H; Chen J
    Biomed Res Int; 2021; 2021():4532438. PubMed ID: 34917682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Tumor Microenvironments between Primary Tumors and Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma and Their Predictive Role in Immune Checkpoint Inhibitor Treatment.
    Kim DH; Ahn JS; Kang M; Park G; Lim Y; Hwang S; Ock CY; Koh J; Chung EJ; Kwon SK; Jeon YK; Jung KC; Ahn SH; Keam B
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Immune Cell Populations in Tumor Tissue and Peripheral Blood Samples from Head and Neck Squamous Cell Carcinoma Patients.
    Caruntu A; Moraru L; Surcel M; Munteanu A; Tanase C; Constantin C; Zurac S; Caruntu C; Neagu M
    Anal Cell Pathol (Amst); 2021; 2021():2328218. PubMed ID: 34692375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy.
    Chen YP; Wang YQ; Lv JW; Li YQ; Chua MLK; Le QT; Lee N; Colevas AD; Seiwert T; Hayes DN; Riaz N; Vermorken JB; O'Sullivan B; He QM; Yang XJ; Tang LL; Mao YP; Sun Y; Liu N; Ma J
    Ann Oncol; 2019 Jan; 30(1):68-75. PubMed ID: 30407504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin Effects on FOXP3
    Amin D; Richa T; Mollaee M; Zhan T; Tassone P; Johnson J; Luginbuhl A; Cognetti D; Martinez-Outschoorn U; Stapp R; Solomides C; Rodeck U; Curry J
    Laryngoscope; 2020 Sep; 130(9):E490-E498. PubMed ID: 31593308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
    Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
    Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization and Differentiation of the Tumor Microenvironment (TME) of Orthotopic and Subcutaneously Grown Head and Neck Squamous Cell Carcinoma (HNSCC) in Immunocompetent Mice.
    Brand M; Laban S; Theodoraki MN; Doescher J; Hoffmann TK; Schuler PJ; Brunner C
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TNF Patterns and Tumor Microenvironment Characterization in Head and Neck Squamous Cell Carcinoma.
    Long Q; Huang C; Meng Q; Peng J; Yao F; Du D; Wang X; Zhu W; Shi D; Xu X; Qi X; Deng W; Chen M; Li Y; Yang A
    Front Immunol; 2021; 12():754818. PubMed ID: 34691075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel immune-related long non-coding RNA signature improves the prognosis prediction in the context of head and neck squamous cell carcinoma.
    Chen L; Cai Z; Lyu K; Cai Z; Lei W
    Bioengineered; 2021 Dec; 12(1):2311-2325. PubMed ID: 34167440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.